Voxzogo approved by the European Commission
2021-08-28Medicine
BioMarin announced August 27, 2021, that the European Commission (EC) has granted marketing authorization for VOXZOGO® (vosoritide) for the treatment of children with achondroplasia starting at age of 2 years until the closure of growth plates, which occurs after puberty. This treatment is administered once a day by injection.
Health Supervision for People With Achondroplasia
2020-06-02Medicine
The American Academy of Pediatrics (APP) Council on Genetics published an update of the clinical report "Health Supervision for Children With Achondroplasia" by Trotter T & Hall J, 2005, on the June 2020 issue of Pediatrics. This clinical report offers age group-specific guidance, including information on counseling expectant parents.
Беременность при ахондроплазии
2018-01-18Medicine
Беременность при ахондроплазии может вызывать настоящий страх: дышать в третьем триместре может быть трудно, кесарева сечения не избежать, а анестезия может быть сопряжена с осложнениями. Однако часть их можно свести к минимуму. Ниже мы описали два случая беременности у женщин с ахондроплазией, которые родили двух здоровых детей. […]